Research ArticleOriginal Article
Open Access

The prognostic significance of p63 cytoplasmic expression in colorectal cancer

An immunohistochemical study

Abdulkader M. Albasri, Mohammed A. Elkablawy, Irfan A. Ansari, Ahmed S. Alhujaily and Amal A. Khalil
Saudi Medical Journal May 2019, 40 (5) 432-439; DOI: https://doi.org/10.15537/smj.2019.5.24162

References

  1. ↵
    1. Ferlay J,
    2. Soerjomataram I,
    3. Ervik M,
    4. Dikshit R,
    5. Eser S,
    6. Mathers C,
    7. et al.
    (2012) GLOBOCAN. Cancer incidence and mortality worldwide (International Agency for Research on Cancer, Lyon (FR)).
  2. ↵
    1. Bray F,
    2. Ren JS,
    3. Masuyer E,
    4. Ferlay J
    (2013) Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133–1145.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Ibrahim EM,
    2. Zeeneldin AA,
    3. El-Khodary TR,
    4. Al-Gahmi AM,
    5. Bin Sadiq BM
    (2008) Past, present and future of colorectal cancer in the Kingdom of Saudi Arabia. Saudi J Gastroenterol 14:178–182.
    OpenUrl
  4. ↵
    Saudi Health Council. Annual Cancer Incidence Report for Saudi Cancer Registry (SCR), Available from https://nhic.gov.sa/eServices/Documents/2014.pdf. (Updated 2014; Accessed 2018 November 11).
  5. ↵
    1. Albasri A,
    2. Yosef H,
    3. Hussainy AS,
    4. Sultan SA,
    5. Alhujaily A
    (2014) Histopathological features of colorectal cancer in Al-Madinah region of Saudi Arabia:8 years experience. Asian Pac J Cancer Prev 15:3133–3137.
    OpenUrl
  6. ↵
    1. Soussi T,
    2. Wiman KG
    (2015) TP53:an oncogene in disguise. Cell Death Differ 22:1239.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Yougong C,
    2. Shijie P,
    3. Yimin F,
    4. Zhi-Xiong L,
    5. Chenghua X
    (2018) double dealing tale of p63:an oncogene or a tumor suppressor. Cell Mol Life Sci 75:965–973.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Massion PP,
    2. Taflan PM,
    3. Jamshedur Rahman SM,
    4. Yildiz P,
    5. Shyr Y,
    6. Edgerton ME,
    7. et al.
    (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63:7113–7121.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Reis-Filho JS,
    2. Simpson PT,
    3. Martins A,
    4. Preto A,
    5. Gärtner F,
    6. Schmitt FC
    (2003) Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443:122–132.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Bergholz J,
    2. Xiao ZX
    (2012) Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron 5:311–322.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Carneiro FP,
    2. Ramalho LN,
    3. Britto-Garcia S,
    4. Ribeiro-Silva A,
    5. Zucoloto S
    (2006) Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum 49:588–594.
    OpenUrlPubMed
  12. ↵
    1. Guo HQ,
    2. Huang GL,
    3. Liu OF,
    4. Liu YY,
    5. Yao ZH,
    6. Yao SN,
    7. et al.
    (2012) p63 Expression is a prognostic factor in colorectal cancer. Int J Biol Markers 27:212–218.
    OpenUrl
  13. ↵
    1. Bahnassy AA,
    2. Zekri AR,
    3. Salem SE,
    4. Abou-Bakr AA,
    5. Sakr MA,
    6. Abdel-Samiaa AG,
    7. et al.
    (2014) Differential expression of p53 family proteins in colorectal adenomas and carcinomas:Prognostic and predictive values. Histol Histopathol 29:207–216.
    OpenUrlPubMed
  14. ↵
    1. Elkablawy MA,
    2. Albasri AM
    (2015) High quality tissue miniarray technique using a conventional TV/radio telescopic antenna. Asian Pac J Cancer Prev 16:1129–1133.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Albasri AM,
    2. Elkablawy MA,
    3. Hussainy AS,
    4. Yousif HM,
    5. Alhujaily AS
    (2018) Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients:An experience from Western Saudi Arabia. SaudiMed J 39:773–780.
    OpenUrl
  16. ↵
    1. Ye S,
    2. Lee KB,
    3. Park MH,
    4. Lee JS,
    5. Kim SM
    (2014) p63 regulates growth of esophageal squamous carcinoma cells via the Akt signaling pathway. Int J Oncol 44:2153–2159.
    OpenUrl
  17. ↵
    1. Fabbro M,
    2. Henderson BR
    (2003) Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282:59–69.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Hood JK,
    2. Silver PA
    (2000) Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim Biophys Acta 1471:M31–M41.
    OpenUrlPubMed
  19. ↵
    1. Prall F,
    2. Hühns M
    (2019) Quantitative evaluation of TP53 immunohistochemistry to predict gene mutations:lessons learnt from a series of colorectal carcinomas. Hum Pathol 84:246–253.
    OpenUrl
    1. Inoue T,
    2. Stuart J,
    3. Leno R,
    4. Maki CG
    (2002) Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 277:15053–15060.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Narahashi T,
    2. Niki T,
    3. Wang T,
    4. Goto A,
    5. Matsubara D,
    6. Funata N,
    7. et al.
    (2006) Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 49:349–57.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Dhillon PK,
    2. Barry M,
    3. Stampfer MJ,
    4. Perner S,
    5. Fiorentino M,
    6. Fornari A,
    7. et al.
    (2009) Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 18:595–600.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Stindt MH,
    2. Muller PA,
    3. Ludwig RL,
    4. Kehrloesser S,
    5. Dötsch V,
    6. Vousden KH
    (2015) Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene 34:4300–4310.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lo Muzio L,
    2. Santarelli A,
    3. Caltabiano R,
    4. Rubini C,
    5. Pieramici T,
    6. Trevisiol L,
    7. et al.
    (2005) p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 36:187–194.
    OpenUrlCrossRefPubMed
    1. Koga F,
    2. Kawakami S,
    3. Kumagai J,
    4. Takizawa T,
    5. Ando N,
    6. Arai G,
    7. et al.
    (2003) Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 88:740–747.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Sethi I,
    2. Romano RA,
    3. Gluck C,
    4. Smalley K,
    5. Vojtesek B,
    6. Buck MJ,
    7. Sinha S
    (2015) A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics 16:584.
    OpenUrlCrossRef
  27. ↵
    1. Agilent Dako
    Monoclonal Mouse Anti-Human p63 Protein. Clone 4A4 (product information), Available from http://www.dako.com/download.pdf?objectid=112041003. [Accessed 2018 November 13].
  28. ↵
    1. Glickman JN,
    2. Yang A,
    3. Shahsafaei A,
    4. McKeon F,
    5. Odze RD
    (2001) Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 11:1157–1165.
    OpenUrl
  29. ↵
    1. Ferronika P,
    2. Triningsih FX,
    3. Ghozali A,
    4. Moeljono A,
    5. Rahmayanti S,
    6. Shadrina AN,
    7. et al.
    (2012) p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Asian Pac J Cancer Prev 13:1943–1948.
    OpenUrlPubMed
  30. ↵
    1. Ribeiro-Silva A,
    2. ZambelliRamalho LN,
    3. Britto Garcia S,
    4. Zucoloto S
    (2003) The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 3:336–340.
    OpenUrl
    1. Wang BY,
    2. Gil J,
    3. Kaufman D,
    4. Gan L,
    5. Kohtz DS,
    6. Burstein DE
    (2002) P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33:921–926.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Xia W,
    2. Chen JS,
    3. Zhou X,
    4. Sun PR,
    5. Lee DF,
    6. Liao Y,
    7. Zhou BP,
    8. Hung MC
    (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10:3815–3824.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Re M,
    2. Zizzi A,
    3. Ferrante L,
    4. Stramazzotti D,
    5. Goteri G,
    6. Gioacchini FM,
    7. Olivieri F,
    8. Magliulo G,
    9. Rubini C
    (2014) p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival. European Archives of Oto-Rhino-Laryngology 271:1641–1651.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Melling N,
    2. Kowitz CM,
    3. Simon R,
    4. Bokemeyer C,
    5. Terracciano L,
    6. Sauter G,
    7. Izbicki JR,
    8. Marx AH
    (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology 69:209–214.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Andreyev HJ,
    2. Norman AR,
    3. Cunningham D,
    4. Oates J,
    5. Dix BR,
    6. Iacopetta BJ,
    7. Young J,
    8. Walsh T,
    9. Ward R,
    10. Hawkins N,
    11. et al.
    (2001) Kirsten ras mutations in patients with colorectal cancer:the 'RASCAL II'study. Br J Cancer 85:692–696.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Shen B,
    2. Li M,
    3. Wang H,
    4. Xin L,
    5. Xie J
    (2018) Expression and clinical significance of the RAS/RAF/MAPK cell signaling pathway in gastric cancer. Int J Clin Exp Med 11:11682–11689.
    OpenUrl
  37. ↵
    1. Lan YT,
    2. Jen Kou L,
    3. Lin CH,
    4. Yang SH,
    5. Lin CC,
    6. Wang HS,
    7. Chen WS,
    8. Lin TC,
    9. Jiang JK,
    10. Chang SC
    (2015) Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol 111:905–910.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section